Cantargia announces full recruitment of CAN04 monotherapy arm in ongoing phase IIa clinical trial

06:32 EDT 5 Jul 2019 | Pharmaceutical Business Review

Here, CAN04 is examined as monotherapy or in chemotherapy combinations in patients with non-small cell lung cancer (NSCLC) or pancreatic cancer (PDAC). All 20 patients planned for one

More From BioPortfolio on "Cantargia announces full recruitment of CAN04 monotherapy arm in ongoing phase IIa clinical trial"